Ir directamente a la navegación principal
Ir directamente a la búsqueda
Ir directamente al contenido principal
Pontificia Universidad Javeriana Inicio
Ayuda y preguntas frecuentes
Español
English
Inicio
Perfiles
Unidades
Productos
Proyectos
Laboratorios y Equipos
Cursos
Actividades
Premios
Medios
Conjuntos de datos
Impacto
Tesis
Buscar por experiencia, nombre o afiliación
PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS
kConFab Investigators66
, Australian Ovarian Cancer Study Group65,66
Instituto de Genética Humana
INSTITUTO DE GENETICA HUMANA - FACULTAD DE MEDICINA - PONTIF
University of Melbourne
University of Utah
University of Oulu
Mayo Clinic Rochester, MN
University of Cambridge
McGill University
Strangeways Research Laboratory
University of Pretoria
Helsinki University Hospital
Hannover Medical School
Ghent University
Memorial Sloan-Kettering Cancer Center
IRCCS Fondazione Istituto Nazionale per lo studio e la cura dei tumori - Milano
FIRC Institute of Molecular Oncology
Antoni van Leeuwenhoek Hospital
University of Sydney
University of Newcastle
Friedrich-Alexander University Erlangen-Nürnberg
University of California at Los Angeles
London School of Hygiene and Tropical Medicine
Institute of Cancer Research
Guy's and St Thomas' NHS Foundation Trust
University of Oxford
University of Porto
University Hospital Galway
Heidelberg University
German Cancer Research Center
National Institute of Health Bogotá
APHP – Paris Saclay University
Copenhagen University Hospital – Herlev and Gentofte
Centro de Investigación en Red de Enfermedades Raras
Centre for Biomedical Research on Rare Diseases (CIBERER)
Hospital Universitario La Paz
Hospital Monte Naranco
University of California, Irvine
City of Hope National Med Center
Cancer Prevention Institute of California
Saarland Cancer Registry
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
University of Tübingen
Ruhr University Bochum
Evangelical Clinics of Bonn
The N.N. Alexandrov Research Institute of Oncology and Medical Radiology
Karolinska Institutet
University of Eastern Finland
QIMR Berghofer Medical Research Institute
VIB Department of Molecular Microbiology
KU Leuven
University Hospitals Leuven
University of Hamburg
Alfred Health
Keck School of Medicine of USC
University of Hawai'i at Mānoa
University of Oslo
Vanderbilt University
Harvard University
Brigham and Women’s Hospital
Samuel Lunenfeld Research Institute
University of Toronto
University Health Network
Leiden University
Erasmus University Rotterdam
Erasmus MC Cancer Institute
National Cancer Institute (NCI)
Maria Sklodowska-Curie Institute of Oncology
University of Southampton, Faculty of Medicine
Genome Institute of Singapore
University of Sheffield
Frauenklinik der Stadtklinik Baden-Baden
Städtischen Klinikum Karlsruhe
Pomeranian Medical University in Szczecin
Medical University of Warsaw
Ohio State University
Roswell Park Cancer Institute
Demokritos National Centre for Scientific Research
Research Center
Department of Breast Surgery
University of Warwick
University of Turku
Tampere University
Turku University Hospital
University of Utah School of Medicine
Cancer Research UK Cambridge Institute
University of Bristol
Fred Hutchinson Cancer Research Center
University of Washington
International Epidemiology Institute
University of Pittsburgh
Ulm University
Washington University St. Louis
H. Lee Moffitt Cancer Center & Research Institute
Medical University Sofia
Queensland University of Technology
North Region Cancer Registry, Portuguese Oncology Institute
Louisiana State University Health Sciences Center
Dartmouth College
Universität Ulm
John A. Burns School of Medicine
Cedars-Sinai Medical Center
Jena University Hospital
University of Texas Health Science Center at Houston
Kliniken Essen-Mitte
Dr. Horst Schmidt Klinik GmbH
Danish Cancer Society
Rigshospitalet
University of Copenhagen
European Institute of Oncology
Cogentech Cancer Genetic Test Laboratory
University of Kansas
Texas Southern University
MD Anderson Cancer Center
Duke University
Duke Cancer Institute
Rutgers - The State University of New Jersey, New Brunswick
University of Bergen
University of Bergen
Radboud University Nijmegen
Netherlands Comprehensive Cancer Organisation
Oregon Health and Science University
BC Cancer
Simon Fraser University
Medical University of South Carolina
University of New Mexico
Peter Maccallum Cancer Centre
University of Glasgow
Beatson Oncology Centre
Stanford University School of Medicine
University of South Florida
Public Health Ontario
University College London
Royal Melbourne Hospital
Cancer Council Victoria
Producción
:
Contribución a una revista
›
Artículo
›
revisión exhaustiva
188
Citas (Scopus)
Información general
Huella
Huella
Profundice en los temas de investigación de 'PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS'. En conjunto forman una huella única.
Clasificar por
Ponderación
Alfabéticamente
Keyphrases
Cancer Risk
100%
PALB2
100%
CHEK2
100%
Rare Variants
100%
Rare Cancer
100%
Risk Data
100%
Breast Cancer Risk
71%
Family Study
14%
Relative Risk
14%
Ovarian Cancer
14%
BRCA2 mutation
14%
Clinically Significant
14%
Population-based
14%
Prostate
14%
Prostate Cancer Risk
14%
Multicenter Case-control Study
14%
Rare mutation
14%
European Women
14%
African Men
14%
INIS
data
100%
risks
100%
cancer
100%
breasts
50%
control
40%
mutations
40%
men
20%
ovaries
20%
prostate
20%
populations
10%
genes
10%
women
10%
Mathematics
Relative Risk
100%
Control Study
100%
Strong Evidence
100%
Medicine and Dentistry
Cancer Risk
100%
Breast Cancer
62%
Case-Control Study
12%
Ovarian Cancer
12%
Prostate Cancer
12%
BRCA2
12%